The current results might only be based on trial studies 3 , 4
It remains uncertain whether the lack of improvements in CV death associated with intensive glycemic control in individuals with T2D also extends to those with prediabetes or to interventions involving newer pharmacological agents such as GLP-1RAs and SGLT2 inhibitors (7477)
What this means for you Coverage should be available with prior authorization
Sokos GG, Bolukoglu H, German J, Hentosz T, Magovern GJ, Maher TD, Dean DA, Bailey SH, Marrone G, Benckart DH, Elahi D, Shannon RP: Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting